The SEC has opened a public comment period on Canary’s proposed staked Injective ETF, inviting feedback within 21 days while the agency reviews the filing for up to 90 days; if approved, the ETF would track INJ and list on the Cboe BZX Exchange, expanding staking-focused regulated products.
-
SEC begins formal review and 21-day public comment window on Canary’s staked Injective ETF.
-
The ETF would track Injective’s native token (INJ) and, if approved, list on the Cboe BZX Exchange.
-
INJ trades near $13.33, retesting key Fibonacci and moving-average supports amid weakening momentum.
staked Injective ETF news: SEC opens comment period on Canary’s filing — read the implications for INJ price and staking ETFs; stay informed with COINOTAG.
What is Canary’s staked Injective ETF proposal?
The staked Injective ETF proposed by Canary would hold Injective’s native token (INJ) and incorporate staking mechanisms to pass rewards to holders while aiming to list on the Cboe BZX Exchange. The U.S. Securities and Exchange Commission has opened a 21-day public comment window and has up to 90 days to decide next steps.
How does the SEC review process and public comment period work?
The SEC’s review begins once a filing is accepted for comment. The 21-day public comment period allows stakeholders to submit views; the agency may extend review up to 90 days before issuing an order or notice. This procedural timeline is standard for exchange-listed ETF proposals under current SEC practice.
Why does Canary say Injective is less prone to manipulation?
Canary’s August filing cites Injective’s roughly $1.4 billion market capitalization, continuous and geographically dispersed trading, and liquidity metrics as reasons that manipulation would be costly and less likely. The filing argues these factors support a fair-value trading environment suitable for an ETF structure.
How could a staked Injective ETF affect INJ price and market structure?
Approval could increase institutional access to Injective exposure, potentially adding custody, compliance, and staking demand. However, short-term price moves will also reflect macro factors and Ethereum-driven sentiment cited by market analysts.
| Item | Detail |
|---|---|
| Proposal sponsor | Canary |
| Target asset | Injective (INJ) — native token |
| Exchange | Cboe BZX Exchange (if approved) |
| Regulatory status | SEC review; 21-day public comment window; up to 90-day review |
| Market cap cited | ~$1.4 billion (Canary filing) |
What are the current technical levels and market risks for INJ?
Injective trades near $13.33 after falling from resistance at $16.85, marking an 8.69% daily decline. Technical supports include a 0.618 Fibonacci retracement near $14.37, with deeper cushions around $10.97 and $8.93–$6.64. Sustained defense of the $13–14 range is critical to avoid larger losses.
Frequently Asked Questions
When did the SEC begin review of the filing?
The SEC accepted Canary’s proposal for review and opened a 21-day public comment window; the filing was submitted in August and is now under agency consideration.
Who are comparable firms pursuing staking ETFs?
Other market participants mentioned in recent filings include VanEck, the Jito Foundation (JitoSOL), and REX-Osprey, which have submitted staking-focused ETF and S-1 materials in similar product categories.
Key Takeaways
- SEC review initiated: Canary’s staked Injective ETF is in a formal 21-day comment period with up to 90 days of review.
- Market implications: Approval could broaden institutional access to INJ and introduce staking yields into an exchange-listed product.
- Technical risk: INJ is under pressure at $13.33; defending the $13–14 band is essential to avoid deeper declines.
Conclusion
The SEC’s review of Canary’s staked Injective ETF marks another regulatory step in bringing staking-based products into regulated markets. Investors should monitor the 21-day comment period, technical price action around key supports, and related staking ETF filings from other sponsors. COINOTAG will update this story as new filings or SEC actions occur.
Author: COINOTAG — Maxwell Mutuma | Published: 25 August 2025 | Updated: 25 August 2025
